High-growth, GACP/EU-GMP-certified pharma cannabis company in Portugal seeks strategic partner

Established, Portuguese pharmaceutical cannabis company positioned to grow rapidly and meet the stringent quality requirements of international medical cannabis markets

Company is completing a binding transaction for the full acquisition of a well-established business with a state-of-the-art, 5,000 m² GACP/EU-GMP-certified indoor facility in Portugal

Facility features multiple GACP cultivation rooms, EU-GMP-compliant post-harvesting areas for drying, trimming, and an R&D lab

Business has been operational since 2020 and achieved GMP certification in 2023, able to produce 2,000 KG/yr of craft quality cannabis (with expansion capacity to 10,000 KG)

Secured multi-year supply contracts projected to generate total revenue of €30M+

Existing distribution and commercial agreements in place with key markets, including Germany, Poland, Portugal, Switzerland, and Australia, with ongoing entry into the UK market

The production capacity of Phase 1 is fully fulfilled, driving the need to accelerate the expansion plan to address growing demand.

There is an option to leverage another facility owned by affiliated stakeholders, creating capacity for a strategic partner to utilize part of the company’s facility's overall production capabilities

Team with deep expertise in the cannabis and pharma sectors with access to a network of licensed facilities in Europe and the US, and executives from the big pharma industry

Site has an approved expansion plan to scale up to 10,000 kg per year (permit already secured for the extension facility) projected to generate €30 million+ of revenue per year

Site features installed solar panels delivering up to 35% annual electricity savings while promoting sustainability

Development plan to acquire a distributor in European key market, projected to generate >€50 million of revenue per year overall.

This opportunity seeks a strategic equity partner to accelerate growth plans.